1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0272-6386(99)70329-x</a> Pages E8–E8 Issue 2 Volume 33 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine. Publisher An entity responsible for making the resource available American journal of kidney diseases : the official journal of the National Kidney Foundation Date A point or period of time associated with an event in the lifecycle of the resource 1999 1999-02 Subject The topic of the resource Antineoplastic Agents/*therapeutic use; B-Cell/*complications; Biopsy; Chronic; Female; Glomerulonephritis; Humans; Kidney/pathology; Leukemia; Lymphocytic; Membranous/diagnosis/*drug therapy/etiology; Vidarabine/*analogs & derivatives/therapeutic use Creator An entity primarily responsible for making the resource Butty H; Asfoura J; Cortese F; Doyle M; Rutecki G Description An account of the resource In some individuals, chronic lymphocytic leukemia (CLL) may be associated with glomerular disease from membranous nephropathy with resultant nephrotic syndrome. CLL is characterized by abnormal immunoregulation with a malignant clonal proliferation of lymphocytes. The association between the abnormal clone and nephrotic syndrome is suggested in some cases by the remission of proteinuria with a reduction in abnormal lymphocyte number after treatment with antineoplastic agents. For the first time, we describe a patient with CLL and associated membranous glomerulopathy whose nephrotic syndrome remitted after treatment with fludarabine, a new purine analogue used in the treatment of refractory CLL. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">10.1016/s0272-6386(99)70329-x</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 1999 American journal of kidney diseases : the official journal of the National Kidney Foundation Antineoplastic Agents/*therapeutic use Asfoura J B-Cell/*complications Biopsy Butty H Chronic Cortese F Department of Internal Medicine Doyle M Female Glomerulonephritis Humans Kidney/pathology Leukemia Lymphocytic Membranous/diagnosis/*drug therapy/etiology NEOMED College of Medicine Rutecki G Vidarabine/*analogs & derivatives/therapeutic use